Said Sebti, Ph.D.
Associate director for basic research, VCU Massey Cancer Center
Lacy Family Endowed Chair of Cancer Research
Research program member: Developmental Therapeutics
1112 E. Clay St.
Richmond, VA 23298
Professor, Pharmacology and Toxicology, School of Medicine
PhD, Purdue University (1984)
My research is focused on: 1) Understanding the mechanisms by which aberrant signal transduction pathways, particularly those mediated by small GTPases (KRas), contribute to the onset of cancer, and 2) Developing novel anticancer drugs based on interference with these pathways. The lab expertise spans from drug design and discovery to validation in human cancer cells, animal models, and biomarker-driven human clinical trials of novel anticancer drugs. The following are examples of research programs pursued in my laboratory: 1) Understanding how GTPases, such as K-Ras, Ral and Rho, cause cancer, 2) Understanding the mechanism by which KRas regulates the tumor suppressor p53, 3) Designing drugs that bind directly to KRas, interfere with binding to its effectors and/or inhibit kinases and other proteins that are synthetic lethal to KRas to kill tumors addicted to mutant KRas, 4) Discovering cell surface proteins whose expression is specific for mutant KRas addicted human tumors, 5) Identifying diagnostic tools to detect human tumors that harbor mutant K-Ras, 6) Developing novel anticancer drugs based on blocking the following cancer-causing proteins: Akt, RhoK, and Aurora kinases, STAT3, Bcl/Mcl, FTase, GGTase and the proteasome, and 7) Combining targeted therapy with chemo and immune therapies to treat cancer.
Apoptosis,Biomarkers,Cancer cell biology,Cancer therapy resistance,Cell signaling,Chemical biology,Clinical trials,Drug discovery,Molecular medicine,Oncogenes,Precision medicine,Proteomics,Screening,Signal transduction,Targeted therapies,Translational science,Tumor suppressors